[1]李燕,张晓雷,李艳斐.右归丸加减联合玉屏风散治疗肺肾气虚证慢性阻塞性肺疾病临床研究[J].陕西中医,2026,(4):477-482.[doi:DOI:10.3969/j.issn.1000-7369.2026.04.008]
　LI Yan,ZHANG Xiaolei,LI Yanfei.Clinical observation on the treatment of chronic obstructive pulmonary disease with lung-kidney qi deficiency syndrome by modified Yougui pill combined with Yupingfeng powder[J].,2026,(4):477-482.[doi:DOI:10.3969/j.issn.1000-7369.2026.04.008]
点击复制

右归丸加减联合玉屏风散治疗肺肾气虚证慢性阻塞性肺疾病临床研究

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2026年4期
页码:
477-482
栏目:
临床研究
出版日期:
2026-04-05

文章信息/Info

Title:
Clinical observation on the treatment of chronic obstructive pulmonary disease with lung-kidney qi deficiency syndrome by modified Yougui pill combined with Yupingfeng powder
作者:
李燕1; 张晓雷1; 李艳斐2
（1.北京中医医院怀柔医院,北京 101400；2.中国中医科学院望京医院,北京 100102)
Author(s):
LI Yan1; ZHANG Xiaolei1; LI Yanfei2
(1.Huairou District Traditional Chinese Medicine Hospital,Beijing 101400,China;2.Wangjing Hospital,Chinese Academy of Traditional Chinese Medicine,Beijing 100102,China)
关键词:
慢性阻塞性肺疾病; 肺肾气虚证; 右归丸; 玉屏风散; 肺功能; 气道重塑
Keywords:
Chronic obstructive pulmonary disease; Lung-kidney qi deficiency syndrome; Yougui pill; Yupingfeng powder; Pulmonary function; Airway remodeling
分类号:
R 256.1
DOI:
DOI:10.3969/j.issn.1000-7369.2026.04.008
文献标志码:
A
摘要:
目的：探讨右归丸加减联合玉屏风散治疗肺肾气虚证慢性阻塞性肺疾病（COPD）的临床疗效。方法：选取82例肺肾气虚证COPD患者作为研究对象，采用随机数字表法分为对照组（n=41，西药治疗）和观察组（n=41，西药+右归丸加减联合玉屏风散治疗），两组均治疗2个月。比较两组患者临床疗效、中医证候积分、治疗后6个月内急性加重次数、肺功能、炎症因子、气道重塑指标、免疫状态及用药不良反应发生情况。结果：观察组临床疗效显著优于对照组（P＜0.05）。观察组主症积分、次症积分、总积分及轻度、中度、重度急性加重次数、肿瘤坏死因子-α（TNF-α）、白细胞介素（IL）-6、IL-17、基质金属蛋白酶-9（MMP-9）、碱性成纤维细胞生长因子（b-FGF）低于对照组（均P＜0.05）。观察组第一秒用力呼气容积（FEV1）、用力肺活量（FVC）、FEV1/FVC、CD4+/CD8+、CD4+、CD3+水平显著高于对照组（均P＜0.05）。结论：右归丸加减联合玉屏风散对肺肾气虚证COPD患者具有良好的治疗价值，可显著降低炎症因子及气道重塑指标水平，改善免疫功能及肺功能，减少急性加重次数，缓解临床症状。
Abstract:
Objective:Exploring the clinical efficacy of modified Yougui pill combined with Yupingfeng powder in the treatment of chronic obstructive pulmonary disease (COPD) with lung-kidney qi deficiency syndrome.Methods:Eighty-two patients with COPD of the syndrome of qi deficiency of the lung and kidney were selected as the research subjects.They were divided into a control group (n=41,treated with western medicine) and an observation group (n=41,treated with western medicine plus modified Yougui pill combined with Yupingfeng powder) by the random number table method.Both groups were treated for 2 months.The clinical efficacy,TCM syndrome scores,number of acute exacerbations within 6 months after treatment,pulmonary function,inflammatory factors,airway remodeling indicators,immune status,and incidence of adverse drug reactions were compared between the two groups.Results:The clinical efficacy of the observation group was significantly better than that of the control group (P<0.05).The scores of main symptoms,secondary symptoms,total scores,the number of mild, moderate and severe acute exacerbations,tumor necrosis factor-α (TNF-α),interleukin (IL)-6,IL-17,matrix metalloproteinase-9 (MMP-9) and basic fibroblast growth factor (b-FGF) in the observation group were lower than those in the control group (all P<0.05).The levels of forced expiratory volume in one second (FEV1),forced vital capacity (FVC),FEV1/FVC,CD4+/CD8+,CD4+ and CD3+ in the observation group were significantly higher than those in the control group (all P<0.05).Conclusion:Modified Yougui pill combined with Yupingfeng powder have good therapeutic value for patients with COPD of lung-kidney Qi deficiency syndrome.They can significantly reduce the levels of inflammatory factors and airway remodeling indicators,improve immune function and lung function,reduce the number of acute exacerbations,and relieve clinical symptoms.

参考文献/References:

[1]方小谦，唐鸿，祝颖，等.风咳方联合沙美特罗替卡松对稳定期哮喘-慢阻肺重叠征患者血清外泌体miR-34a和细胞因子的影响[J].陕西中医，2025，46(8):1053-1057.
[2]CAO X，WANG Y，CHEN Y，et al.Advances in traditional Chinese medicine for the treatment of chronic obstructive pulmonary disease[J].J Ethnopharmacol，2023，30(7):116229.
[3]潘子涵，李姝润，陈亚红.物联网技术在慢性阻塞性肺疾病管理中的研究进展与展望[J].中国全科医学，2024，27(35):4446-4454.
[4]QIAN Y，CAI C，SUN M，et al.Analyses of factors associated with acute exacerbations of chronic obstructive pulmonary disease:A review[J].Int J Chron Obstruct Pulmon Dis,2023，18(21):2707-2723.
[5]欧阳张宁，高凌云.抗胆碱能支气管扩张剂在慢性阻塞性肺疾病稳定期治疗中的应用进展[J].医学综述，2023，29(15):3027-3031.
[6]中华医学会呼吸病学分会慢性阻塞性肺疾病学组，中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会，陈荣昌，等.慢性阻塞性肺疾病诊治指南(2021年修订版)[J].中华结核和呼吸杂志，2021，44(3):170-205.
[7]李建生，李素云，余学庆.慢性阻塞性肺疾病中医诊疗指南(2011版)[J].中医杂志，2012，53(1):80-84.
[8]SUNJAYA A，POULOS L，REDDEL H，et al.Qualitative validation of the modified Medical Research Council (mMRC) dyspnoea scale as a patient-reported measure of breathlessness severity[J].Respir Med，2022，20(3):106984.
[9]国家食品药品监督管理总局.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社，2002:48-55.
[10]蔡柏蔷，陈荣昌.慢性阻塞性肺疾病急性加重（AECOPD）诊治中国专家共识（2017年更新版）[J].国外医学：呼吸系统分册，2017，37(14):1041-1057.
[11]刘诗文，曹玲君，张传名，等.针刺敏化穴联合火龙灸治疗慢性阻塞性肺疾病疗效及对患者肺功能、炎性反应的影响[J].陕西中医，2025，46(8):1131-1135.
[12]SHAH K P K，BHAT H P，KADAM M，et al.Assessment of the BODE index and its association with inflammatory mediators in chronic obstructive pulmonary disease (COPD) patients[J].Cureus，2024，16(10):e72172.
[13]KUBYSHEVA N I，POSTNIKOVA L B，SOODAEVA S K，et al.Comparative study of the levels of IL-1β，IL-4，IL-8，TNF-α，and IFN-γ in stable course and exacerbation of chronic obstructive pulmonary disease of varying severity[J].Bull Exp Biol Med，2022，173(6):745-748.
[14]吴雨珊，金寿德，强丽霞，等.IL-1β、IL-6及TNF-α在慢性阻塞性肺疾病中的作用及研究进展[J].国际呼吸杂志，2021，41(4):298-303.
[15]杨国林，易何娟.血清CRP、PCT、IL-17对慢性阻塞性肺疾病稳定期患者急性发作的预测作用[J].检验医学与临床，2024，21(7):999-1002.
[16]LATAYAN J，AKKENAPALLY S V，MADALA S K.Emerging concepts in cytokine regulation of airway remodeling in asthma[J].Immunol Rev，2025，330(1):e70020.
[17]周令，李红叶，张雷，等.支气管哮喘患儿血清MMP-9、INF-γ水平对治疗后气道重塑的预测价值[J].郑州大学学报(医学版)，2025，60(1):122-125.
[18]ZHU W，HAN L，WU Y，et al.Keratin 15 protects against cigarette smoke-induced epithelial mesenchymal transformation by MMP-9[J].Respir Res，2023，24(1):297.
[19]赵爽，付玉娜.黄芪活性成分治疗呼吸道感染药理作用的研究进展[J].环球中医药，2024，17(9):1890-1896.
[20]卢平，欧立文，李牛秀，等.黄芪多糖对铜绿假单胞菌致大鼠肺部感染的作用分析[J].中华肺部疾病杂志（电子版），2022，15(3):323-326.
[21]王清泉，宋景，李亚男，等.地黄多糖的提取纯化及药理作用研究进展[J].中草药，2023，54(11):3734-3744.
[22]牟春燕，殷越，沈子芯.当归化学成分及药理作用研究进展[J].山东中医杂志，2024，43(5):544-551.
[23]白维娟，马惠.糖尿病合并慢性阻塞性肺疾病患者分泌型卷曲相关蛋白5、D-二聚体及T淋巴细胞亚群与肺功能、血气水平的关联探究[J].陕西医学杂志，2025，54(10):1395-1399.
[24]王选阳，高原，唐进法，等.黄芪及其药对研究进展[J].中华中医药学刊，2024，43(3):155-160.
[25]王小兰，段鹏飞，杨梦，等.生地黄多糖对环磷酰胺诱导的免疫抑制小鼠的免疫调节作用研究[J].上海中医药大学学报，2021，35(1):55-60.

相似文献/References:

[1]杨栓柱,王 文 △,李 猛,等.千金苇茎汤合瓜蒌薤白杏仁汤治疗 慢性阻塞性肺疾病急性加重期临床研究*[J].陕西中医,2019,(5):600.
[2]王 敏,陈 阁.清热化痰祛瘀方联合西药治疗慢性阻塞性肺疾病急性 加重期患者的临床研究[J].陕西中医,2019,(5):610.
　WANG Min,CHEN Ge..Clinical study of Qingre Huatan Quyu prescription combined with western medicine in the treatment of acute exacerbation of chronic obstructive pulmonary disease[J].,2019,(4):610.
[3]李天浩,韩晨旭,王惠琴,等.基于EGFR-MUC5AC信号通路探讨参鱼化痰口服液干预慢性阻塞性肺疾病大鼠气道黏液高分泌的机制*[J].陕西中医,2019,(8):995.
　LI Tianhao,HAN Chenxu,WANG Huiqin,et al.Based on EGFR-MUC5AC signaling pathway to explore the mechanism of Shenyu Huatan oral liquid in intervention of airway mucus high secretion in COPD rats[J].,2019,(4):995.
[4]王珊珊,谭光波△.补肺汤对慢性阻塞性肺疾病肺气肿大鼠血清IFNγ、IL4表达水平影响研究*[J].陕西中医,2019,(11):1491.
　WANG Shanshan,TAN Guangbo..Effect of Bufei decoction on the expression of IFNγ and IL4 in serum of rats with chronic obstructive pulmonary disease and emphysema[J].,2019,(4):1491.
[5]任英杰,王 起,陈秋生.黄芪汤加减治疗急性加重期慢性阻塞性肺疾病疗效研究[J].陕西中医,2020,(1):57.
　REN Yingjie,WANG Qi,CHEN Qiusheng..Observation on the curative effect of Huangqi decoction in the treatment ofacute exacerbation of chronic obstructive pulmonary disease[J].,2020,(4):57.
[6]聂清华,范伏元△.射干麻黄汤联合沙丁胺醇对慢性阻塞性肺疾病患者肺功能、生活质量的影响[J].陕西中医,2020,(2):180.
　NIE Qinghua,FAN Fuyuan..Effects of Shegan Mahuang decoction and albuterol on pulmonary function and quality of life in patients with COPD[J].,2020,(4):180.
[7]刘新平,王展儒.理肺化痰通脉方治疗慢性阻塞性肺疾病急性加重期临床研究[J].陕西中医,2020,(4):484.
[8]杜沂岚,唐 敏,陈朝晖△,等.经肺腧穴中药离子导入联合振动排痰治疗慢性阻塞性肺疾病急性加重期临床疗效*[J].陕西中医,2020,(4):534.
　DU Yilan,TANG Min,CHEN Zhaohui,et al.Clinical efficacy of Chinese medicine iontophoresis via Feishu point combined with vibration sputum discarding in the treatment of AECOPD[J].,2020,(4):534.
[9]唐颖丽,谢 珊,余清萍,等.子午流注法治疗慢性阻塞性肺疾病加重期痰浊阻肺证疗效研究*[J].陕西中医,2020,(9):1311.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.039]
　TANG Yingli,XIE Shan,YU Qingping,et al.Curative effect of midnight-noon ebb-flow method on chronic obstructive pulmonary disease exacerbation with syndrome of Tanzhuo Zufei[J].,2020,(4):1311.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.039]
[10]蔡东林,孙钟和,赵益庆.慢性阻塞性肺疾病稳定期BODE指数、IL-8、TNF-α水平与肺肾气虚证相关性研究*[J].陕西中医,2020,(11):1573.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.015]

备注/Memo

备注/Memo:
国家中医药管理局科研项目（2013BAI13B021）；黑龙江省中医药管理局科研项目（ZHY2023-154）；北京市怀柔区卫生和计划生育委员会科研项目
更新日期/Last Update: 2026-04-05